Ecofi Investissements SA Has $9.54 Million Stake in Boston Scientific Co. (NYSE:BSX)

Ecofi Investissements SA lowered its position in shares of Boston Scientific Co. (NYSE:BSX) by 19.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 115,300 shares of the medical equipment provider’s stock after selling 27,500 shares during the period. Boston Scientific comprises about 5.9% of Ecofi Investissements SA’s investment portfolio, making the stock its 2nd biggest holding. Ecofi Investissements SA’s holdings in Boston Scientific were worth $9,542,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. TFC Financial Management Inc. raised its position in shares of Boston Scientific by 308.8% in the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 210 shares in the last quarter. Global Wealth Strategies & Associates boosted its holdings in shares of Boston Scientific by 423.7% during the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 250 shares in the last quarter. West Oak Capital LLC purchased a new stake in shares of Boston Scientific in the 4th quarter worth about $29,000. Valley National Advisers Inc. increased its stake in shares of Boston Scientific by 262.4% in the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 286 shares in the last quarter. Finally, Fairway Wealth LLC bought a new position in shares of Boston Scientific during the fourth quarter valued at approximately $36,000. 89.07% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CFO Daniel J. Brennan sold 67,333 shares of Boston Scientific stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $105.24, for a total transaction of $7,086,124.92. Following the sale, the chief financial officer now owns 225,808 shares in the company, valued at approximately $23,764,033.92. The trade was a 22.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP John Bradley Sorenson sold 6,528 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $104.97, for a total value of $685,244.16. Following the completion of the transaction, the executive vice president now directly owns 26,449 shares in the company, valued at approximately $2,776,351.53. The trade was a 19.80 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 133,183 shares of company stock valued at $13,948,476. Company insiders own 0.50% of the company’s stock.

Boston Scientific Stock Down 0.2 %

Shares of BSX stock opened at $95.08 on Friday. The stock’s fifty day moving average price is $99.46 and its 200 day moving average price is $94.34. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. Boston Scientific Co. has a 1-year low of $66.80 and a 1-year high of $107.17. The company has a market cap of $140.63 billion, a price-to-earnings ratio of 76.06, a price-to-earnings-growth ratio of 2.79 and a beta of 0.73.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. On average, research analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on BSX shares. Stifel Nicolaus raised their price objective on shares of Boston Scientific from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. Truist Financial cut their target price on Boston Scientific from $120.00 to $113.00 and set a “buy” rating on the stock in a research note on Friday, April 11th. Needham & Company LLC upgraded Boston Scientific from a “hold” rating to a “buy” rating and set a $113.00 price objective for the company in a report on Wednesday. Piper Sandler upped their target price on shares of Boston Scientific from $95.00 to $115.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. Finally, Wells Fargo & Company boosted their price objective on shares of Boston Scientific from $100.00 to $118.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. One analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $110.22.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.